ADMA Biologics Inc (NASDAQ:ADMA) EVP James Mond bought 4,500 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were acquired at an average cost of $4.00 per share, with a total value of $18,000.00. Following the acquisition, the executive vice president now directly owns 17,889 shares of the company’s stock, valued at $71,556. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ ADMA opened at $4.34 on Wednesday. ADMA Biologics Inc has a 12 month low of $2.08 and a 12 month high of $6.96. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60. The stock has a market capitalization of $190.96 million, a price-to-earnings ratio of -2.99 and a beta of 3.05.
ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.06). ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $4.06 million during the quarter, compared to analyst estimates of $5.19 million. As a group, analysts predict that ADMA Biologics Inc will post -1.24 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth about $177,000. Morgens Waterfall Vintiadis & Co. Inc. lifted its position in shares of ADMA Biologics by 43.8% during the first quarter. Morgens Waterfall Vintiadis & Co. Inc. now owns 575,000 shares of the biotechnology company’s stock worth $2,179,000 after purchasing an additional 175,000 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth about $853,000. ExodusPoint Capital Management LP acquired a new stake in shares of ADMA Biologics during the first quarter worth about $59,000. Finally, Northern Trust Corp lifted its position in shares of ADMA Biologics by 11.1% during the first quarter. Northern Trust Corp now owns 261,571 shares of the biotechnology company’s stock worth $991,000 after purchasing an additional 26,066 shares in the last quarter. 53.19% of the stock is currently owned by institutional investors.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: Gap Down Stocks
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.